Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor-Reference-Cited by-同舟云学术

Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor

Published:2016-01-17 Issue:5 Volume:81 Page:971-979
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Lazaar Aili L.¹,Yang Lucy²,Boardley Rebecca L.³,Goyal Navin S.¹,Robertson Jonathan³,Baldwin Sandra J.³,Newby David E.⁴,Wilkinson Ian B.²,Tal-Singer Ruth¹,Mayer Ruth J.¹,Cheriyan Joseph²³⁵

Affiliation:

1. GSK R&D; King of Prussia Pennsylvania USA

2. Experimental Medicine & Immunotherapeutics, Department of Medicine; University of Cambridge, and Cambridge Clinical Trials Unit; Cambridge

3. GSK R&D; Stevenage Cambridge and Ware

4. University Centre for Cardiovascular Science, University of Edinburgh; Edinburgh UK

5. Cambridge University Hospitals NHS Foundation Trust; Cambridge and

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.12855/fullpdf

Reference41 articles.

1. Impact of Soluble Epoxide Hydrolase and Epoxyeicosanoids on Human Health;Morisseau;Annu Rev Pharmacol Toxicol,2012

2. Stabilized epoxygenated fatty acids regulate inflammation, pain, angiogenesis and cancer;Zhang;Prog Lipid Res,2014

3. Action of epoxyeicosatrienoic acids on cellular function;Spector;Am J Physiol Cell Physiol,2007

4. Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: a promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases?;Bellien;Pharmacol Ther,2011

5. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases;Imig;Nat Rev Drug Discov,2009

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the soluble epoxide hydrolase pathway as a novel therapeutic approach for the treatment of pain;Current Opinion in Pharmacology;2024-10

2. STRUCTURE-BASED DESIGN OF PROTACS FOR THE DEGRADATION OF SOLUBLE EPOXIDE HYDROLASE;2024-09-05

3. In vivo–Active Soluble Epoxide Hydrolase–targeting PROTACs with Improved Potency and Stability;2024-07-24

4. Evaluation of the Therapeutic Potential of Sulfonyl Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors;Molecules;2024-06-26

5. Effects of sEH inhibition on the eicosanoid and cytokine storms in SARS‐CoV‐2‐infected mice;The FASEB Journal;2024-05-24